Kymera Therapeutics (KYMR) grants director 6,068 stock options
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Kymera Therapeutics director Elena Ridloff reported a new equity award. She received a stock option covering 6,068 shares of common stock at an exercise price of 99.87 per share, expiring on June 23, 2036. The option vests in full on the earlier of June 24, 2027 or the next annual stockholder meeting. This is a compensation-related grant, not an open-market purchase or sale, and results in Ridloff holding 6,068 derivative securities directly.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Ridloff Elena
Role
null
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 6,068 | $0.00 | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 6,068 shares (Direct, null)
Footnotes (1)
- [object Object]
Key Figures
Option grant size: 6,068 shares
Exercise price: 99.87 per share
Expiration date: June 23, 2036
+3 more
6 metrics
Option grant size
6,068 shares
Stock option covering Kymera common stock
Exercise price
99.87 per share
Conversion or exercise price of the option
Expiration date
June 23, 2036
Stock option term end date
Underlying shares
6,068 shares
Common stock underlying the option
Post-transaction derivative holdings
6,068 derivative securities
Total options held after grant
Vesting trigger date
June 24, 2027
Latest date for full vesting, absent earlier annual meeting
Key Terms
Stock Option (Right to Buy), grant/award acquisition, Common Stock, exercise price, +1 more
5 terms
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
grant/award acquisition financial
"transaction_action: grant/award acquisition"
Common Stock financial
"underlying_security_title: Common Stock"
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
exercise price financial
"conversion_or_exercise_price: 99.8700"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vest in full financial
"shares underlying this stock option shall vest in full"
FAQ
What insider transaction did Kymera Therapeutics (KYMR) disclose for Elena Ridloff?
Kymera Therapeutics disclosed that director Elena Ridloff received a grant of stock options for 6,068 shares of common stock. The option is a compensation-related award, not an open-market trade, and represents her current reported derivative holdings following the transaction.
What are the key terms of Elena Ridloff’s new Kymera (KYMR) stock option grant?
The grant covers 6,068 underlying shares of Kymera common stock with an exercise price of 99.87 per share. The option expires on June 23, 2036 and vests in full upon a specified future date tied to service as a director.
When do Elena Ridloff’s Kymera stock options vest according to the Form 4?
The stock options vest in full on the earlier of June 24, 2027 or the date of Kymera Therapeutics’ next annual meeting of stockholders. This time-based vesting means full exercisability depends on continued board service until one of those milestones.
What is the expiration date of Elena Ridloff’s Kymera stock options?
The options granted to Elena Ridloff expire on June 23, 2036. After that date, any unexercised portion of the 6,068-share award would lapse, so the long-dated term provides a substantial window to potentially exercise after vesting conditions are met.